Published mark
Viking Therapeutics, Inc.
NASDAQ: VKTX. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:a615e681-715b-43ed-b93f-36b5505293e7
- SEC CIK
- 0001607678
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 7, 2026
- Newest evidence
- Apr 1, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Bradley T. Sheares, Ph.D.Since Apr 1, 2026
- Chair
- Not published
- Independent
- Not published7 directors published
- Published claims
- 252 distinct sources
- Evidence records
- 70 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Brian Lian, Ph.D. seat on Viking Therapeutics, Inc., effective 2026-04-01.
EffectiveEffective Apr 1, 2026E2
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President and Chief Executive Officer, Director | Bradley T. Sheares, Ph.D. | Apr 2026 | current | Source reportedE3 |
| Chief Financial Officer | Greg Zante | Apr 2026 | current | Source reportedE4 |
| Chief Operating Officer | Marianne Mancini | Apr 2026 | current | Source reportedE5 |
| Chief Commercial Officer | Neil Aubuchon | Apr 2026 | current | Source reportedE6 |
Board of directors
Evidence7 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Brian Lian, Ph.D. | Independence not published | 2026 | None published | Source reportedE2 |
| Charles A. Rowland, Jr | Independence not published | 2026 | Audit CommitteeCompensation Committee, chair | Source reportedE2 |
| J. Matthew Singleton | Independence not published | 2014 | Audit Committee, chairCompensation Committee | Source reportedE2 |
| Kathryn Rouan | Independence not published | 2019 | None published | Source reportedE2 |
| Lawson Macartney | Independence not published | 2026 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE2 |
| Matthew W. Foehr | Independence not published | 2014 | None published | Source reportedE2 |
| Neil Aubuchon | Independence not published | 2026 | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | J. Matthew Singleton | J. Matthew Singleton, Charles A. Rowland, Jr, Lawson Macartney, J. Matthew Singleton, Charles A. Rowland, Jr, Lawson Macartney | Not described in the published record |
| Compensation Committee | Charles A. Rowland, Jr | Charles A. Rowland, Jr, J. Matthew Singleton, Lawson Macartney, Charles A. Rowland, Jr, J. Matthew Singleton, Lawson Macartney | Not described in the published record |
| Nominating and Corporate Governance Committee | Not published | Lawson Macartney, Lawson Macartney | Not described in the published record |
Committee RecordAudit Committee: Chair J. Matthew Singleton; Members J. Matthew Singleton (Chair); Charles A. Rowland, Jr; Lawson Macartney
Committee AppointmentJ. Matthew Singleton: chair, Audit Committee
Committee AppointmentCharles A. Rowland, Jr: member, Audit Committee
Committee AppointmentLawson Macartney: member, Audit Committee
Committee RecordCompensation Committee: Chair Charles A. Rowland, Jr; Members Charles A. Rowland, Jr (Chair); J. Matthew Singleton; Lawson Macartney
Committee AppointmentCharles A. Rowland, Jr: chair, Compensation Committee
Committee AppointmentJ. Matthew Singleton: member, Compensation Committee
Committee AppointmentLawson Macartney: member, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair not stated; Members Lawson Macartney
Committee AppointmentLawson Macartney: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerBradley T. Sheares, Ph.D., President and Chief Executive Officer, Director, from Apr 1, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingVKTX (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 7, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameViking Therapeutics, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Bradley T. Sheares, Ph.D.President and Chief Executive Officer, Directorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:12
- Greg ZanteChief Financial Officercompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:13
- Marianne ManciniChief Operating Officercompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:14
- Neil AubuchonChief Commercial Officer; Directorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:15, company:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:11
- Brian Lian, Ph.D.Directorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:5
- Charles A. Rowland, JrDirectorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:6
- J. Matthew SingletonDirectorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:7
- Kathryn RouanDirectorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:8
- Lawson MacartneyDirectorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:9
- Matthew W. FoehrDirectorcompany:a615e681-715b-43ed-b93f-36b5505293e7:leadership_role:10
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 7 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 7, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 1, 2026. Retrieved Sep 2, 2026. Cited by 7 Claims.
- E3sec filing. Published Apr 1, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 1, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 1, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 1, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E7governance_people_committees. sec proxy. Cited by 10 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 7, 2026- Brian Lian, Ph.D. seat on Viking Therapeutics, Inc., effective 2026-04-01.
- Charles A. Rowland, Jr seat on Viking Therapeutics, Inc., effective 2026-04-01.
- Lawson Macartney seat on Viking Therapeutics, Inc., effective 2026-04-01.
- Neil Aubuchon seat on Viking Therapeutics, Inc., effective 2026-04-01.
- Bradley T. Sheares, Ph.D. executive of Viking Therapeutics, Inc., effective 2026-04-01.
- Greg Zante executive of Viking Therapeutics, Inc., effective 2026-04-01.
- Marianne Mancini executive of Viking Therapeutics, Inc., effective 2026-04-01.
- Neil Aubuchon executive of Viking Therapeutics, Inc., effective 2026-04-01.
- Kathryn Rouan seat on Viking Therapeutics, Inc., effective 2019-01-01.
- J. Matthew Singleton seat on Viking Therapeutics, Inc., effective 2014-01-01.
- Matthew W. Foehr seat on Viking Therapeutics, Inc., effective 2014-01-01.